Palifermin Treatment of Toxic Epidermal Necrolysis

Trial Profile

Palifermin Treatment of Toxic Epidermal Necrolysis

Phase of Trial: Phase I/II

Latest Information Update: 02 Dec 2016

At a glance

  • Drugs Palifermin (Primary)
  • Indications Stevens-Johnson syndrome; Toxic epidermal necrolysis
  • Focus Therapeutic Use
  • Sponsors Swedish Orphan Biovitrum
  • Most Recent Events

    • 09 Aug 2016 Status changed from recruiting to discontinued as low enrollment numbers precluded completion of the study during a reasonable amount of time.
    • 17 Feb 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top